Why does sentinel lymph node biopsy not increase patient survival from melanoma?;¿Por qué la biopsia del ganglio centinela no aumenta la supervivencia en pacientes con melanoma?

Actas Dermo-Sifiliograficas

Volumn 99, Issue 5, 2008, Pages 323-330

  Pizarro, Ángel ^a,b,c  

^a Instituto Madrileno de Oncologia   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL EXAMINATION; DIAGNOSTIC TEST; DISEASE COURSE; GENETIC ANALYSIS; HEALTH CARE UTILIZATION; HEALTH SURVEY; HUMAN; IMMUNE SYSTEM; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOMA; MICROMETASTASIS; NOTE; PATHOPHYSIOLOGY; PROGNOSIS; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SKIN BIOPSY; SKIN CARCINOGENESIS; ARTICLE; MORTALITY; PATHOLOGY; SKIN TUMOR; SURVIVAL RATE;

HUMANS; MELANOMA; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 45749147768     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S1578-2190(08)70266-X     Document Type: Article

References (45)

1. Mangas C, Paradelo C, Rex J, Ferrándiz C. La biopsia del ganglio centinela: su papel diagnóstico y pronóstico en el melanoma maligno. Actas Dermosifiliogr. 2008;99:331-48.
2. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer Staging System for cutaneous melanoma. J Clin Oncol. 2001;19:3635-48.
3. Essner R. Sentinel lymph node biopsy and melanoma biology. Clin Cancer Res. 2006;12 Suppl 2:2320s-5s.
4. Ferrándiz C, Mangas C. Utilidad terapéutica directa de la biopsia del ganglio centinela en pacientes con melanoma. Med Clin (Barc). 2006;126:135-6.
5. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-17.
6. Morton DL, Cochran AJ. The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma. Br J Dermatol. 2004;151:308-19.
7. Essner R. Surgical treatment of malignant melanoma. Surg Clin North Am. 2003;83:109-56.
8. Pizarro A, Redondo P. Melanoma dissemination and the usefulness of sentinel lymph node biopsy: a reappraisal. Skin Cancer. 2004;19:221-30.
9. Leong SP. Paradigm of metastasis for melanoma and breast cancer based on the sentinel lymph node experience. Ann Surg Oncol. 2004;11 Suppl:192S-7S.
10. Balch CM, Cascinelli N, Sim FH. Elective lymph node dissection. Results of prospective randomised surgical trials. En: Balch CM, Houghton AN, Sober AJ, Soong SJ, editors. Cutaneous Melanoma. St. Louis, Missouri: Quality Medical Publishing; 2003. p. 379-95.
11. Sleeman JP. The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent Results Cancer Res. 2000;157:55-81.
12. Pizarro A. La biopsia del ganglio centinela desde una perspectiva inmunológica: reticencias injustificadas. Actas Dermosifiliogr. 2005;96:628-30.
13. Navarro P, Gómez M, Pizarro A, Gamallo C, Quintanilla M, Cano A. A role for the E-cadherin cell-cell adhesion molecule during tumor progression of mouse epidermal carcinogenesis. J Cell Biol. 1991;115:517-33.
14. Palacios J, Benito N, Pizarro A, Suárez A, Espada J, Cano A, et al. Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and other pathological features. Am J Pathol. 1995;146;605-12.
15. Pizarro A, Gamallo C, Benito N, Palacios J, Quintanilla M, Cano A, et al. Differential patterns of placental and epithelial cadherin expression in basal cell carcinoma and in the epidermis overlying tumours. Br J Cancer. 1995;72:327-32.
16. Pizarro A. E-cadherin expression in basal cell carcinoma: association with local invasiveness but not with metastatic inefficiency. J Cutan Pathol. 2000;27:479-80.
17. Lens MB, Dawes M, Goodacre T, Newton-Bishop JA. Elective lymph node dissection in patients with melanoma. Systematic review and meta-analysis of randomized controlled trials. Arch Surg. 2002;137:458-61.
18. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12:895-904.
19. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet. 2007;369:1742-57.
20. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7:834-45.
21. Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol. 2002;147:62-70.
22. Tejera-Vaquerizo A, Barrera-Vigo MV, Fernández-Canedo I, Blázquez-Sánchez N, Mendiola-Fernández M, Fernández-Orland A, et al. Estudio temporal de los diferentes patrones metastásicos en la progresión del melanoma cutáneo. Actas Dermosifiliogr. 2007;98:531-8.
23. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. Lancet. 1998;351:793-6.
24. González U. Cloud over sentinel node biopsy. Unlikely survival benefit in melanoma. Arch Dermatol. 2007;143:775-6.
25. Kanzler MH. The current status of evaluation and treatment of high-risk cutaneous melanoma. Therapeutic breakthroughs remain elusive. Arch Dermatol. 2007;143:785-7.
26. Grichnik JM. Sentinel-node biopsy in melanoma. N Engl J Med. 2007;356:418-9.
27. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670-7.
28. Epstein RJ. Maintenance therapy to suppress micrometastasis: the new challenge for adjuvant cancer treatment. Clin Cancer Res. 2005;11:5337-41.
29. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Goikas C, Frangia K, Tsoutsos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709-18.
30. Medalie N, Ackerman AB. Sentinel node biopsy has no benefit for patients whose primary cutaneous melanoma has metastasized to a lymph node and therefore should be abandoned now. Br J Dermatol. 2004;151:298-307.
31. Pharis DB, Zitelli JA. The management of regional lymph nodes in cancer. Br J Dermatol. 2003;149:919-25.
32. McMasters KM. What good is sentinel lymph node biopsy for melanoma if it does not improve survival? Ann Surg Oncol. 2004;11:810-2.
33. Sabel MS, Griffith KA, Arora A, Shargorodsky J, Blazer D, Rees R, et al. Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. Surgery. 2007;141:728-35.
34. Essner R, Scheri R, Kavanagh M, Torisu-Itakura H, Wanek LA, Morton DL. Surgical management of the groin lymph nodes in melanoma in the era of sentinel lymph node dissection. Arch Surg. 2006;141:877-84.
35. Badgwell B, Xing Y, Gershenwald JE, Lee JE, Mansfield PF, Ross MI, et al. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Ann Surg Oncol. 2007;14:2867-75.
36. Pizarro A. La biopsia del ganglio centinela desde una perspectiva inmunológica: ¿optimismo prematuro? Actas Dermosifiliogr. 2003;94:60-2.
37. Alonso SR, Tracey L, Ortiz P, Pérez-Gómez B, Palacios J, Pajares R, et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res. 2007;67:3450-60.
38. Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res. 2007;13:806-14.
39. Fidler IJ. The pathogenesis of cancer metastasis: the «seed and soil» hypothesis revisited. Nat Rev Cancer. 2002;3:453-8.
40. Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell. 2006;127:679-95.
41. Clark WH. Tumour progression and the nature of cancer. Br J Cancer. 1991;64:631-44.
42. Wong SL, Morton DL, Thompson JF, Gershenwald JE, Leong SPL, Reintgen DS, et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol. 2006;13:809-16.
43. Essner R. Experimental frontiers for clinical applications: novel approaches to understanding mechanisms of lymph node metastases in melanoma. Cancer Metastasis Rev. 2006;25:257-67.
44. Harrell MI, Iritani BM, Ruddell A. Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am J Pathol. 2007;170:774-86.
45. Qian CN, Berghuis B, Tsarfaty G, Bruch M, Kort EJ, Ditley J, et al. Preparing the «soil»: the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res. 2006;66:10365-76.